Trial Profile
A Superiority Study of LY248686 [duloxetine] Versus Placebo in the Treatment of Patients With Diabetic Peripheral Neuropathic Pain.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 26 Apr 2011
Price :
$35
*
At a glance
- Drugs Duloxetine (Primary)
- Indications Diabetic neuropathies; Neuropathic pain
- Focus Therapeutic Use
- Sponsors Eli Lilly and Company
- 30 Mar 2011 Actual end date of the extension trial (NCT00641719) is Mar 2010.
- 30 Mar 2011 Actual end date of the extension trial (NCT00641719) is Mar 2010.
- 30 Mar 2011 Actual start date of the extension trial (NCT00641719) is Mar 2008.